Spots Global Cancer Trial Database for A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Official Title: A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Study ID: NCT01351103
Study Description
Brief Summary: The primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that have progressed despite standard therapy or for which no effective standard therapy exists
Detailed Description: This open-label multicenter phase 1 dose escalation study will be the first to administer LGK974 as a single agent or in combination with PDR001 in humans. The study will comprise of 2 parts: a dose escalation of LGK974 as a single agent, followed by a safety expansion in specific disease indications; and a dose escalation of LGK974 in combination with PDR001, followed by a safety expansion in cutaneous melanoma.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCLA School of Medicine, Los Angeles, California, United States
Sidney Kimmel Comprehensive Cancer Center Johns Hopkins, Baltimore, Maryland, United States
Dana Farber Cancer Institute SC-7, Boston, Massachusetts, United States
University of Michigan Comprehensive Cancer Center Onc Dept., Ann Arbor, Michigan, United States
Karmanos Cancer Institute Wayne St, Detroit, Michigan, United States
University of Texas/MD Anderson Cancer Center MD Anderson 2, Houston, Texas, United States
Novartis Investigative Site, Montreal, Quebec, Canada
Novartis Investigative Site, Villejuif, , France
Novartis Investigative Site, Essen, , Germany
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Napoli, , Italy
Novartis Investigative Site, Rotterdam, , Netherlands
Novartis Investigative Site, Utrecht, , Netherlands
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Madrid, , Spain
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
